8-KFiled Aug 12, 8:00 PM ET

Rani Therapeutics Reports Q2 2026 Results

$RANI · Rani Therapeutics Holdings, Inc.

Research Summary

AI-generated summary of this SEC filing

Updated

Rani Therapeutics Reports Q2 2026 Results

What Happened
Rani Therapeutics Holdings, Inc. announced financial results and a corporate update for the three and six months ended June 30, 2026 via a press release issued on August 13, 2026. The press release containing the quarterly results is furnished as Exhibit 99.1 to the Form 8-K and is incorporated by reference. The filing was signed by CFO Nicholas M. Maestas.

Key Details

  • Filing date: August 13, 2026 (Form 8-K, Item 2.02).
  • Reporting period: three and six months ended June 30, 2026 (Q2 2026 and year-to-date).
  • Press release is attached as Exhibit 99.1; Cover Page Interactive Data file is Exhibit 104.
  • Form 8-K signed by Nicholas M. Maestas, Chief Financial Officer.

Why It Matters
This 8-K notifies investors that Rani has released its quarterly earnings and corporate update; investors should review the Exhibit 99.1 press release for the specific earnings figures (revenue, net income/loss), cash position or runway, and any guidance or strategic updates. The Form 8-K itself is a routine mechanism to disclose quarterly results—full financial details and management commentary are in the attached press release.